Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer

Niels E. Wondergem; Iris H.C. Miedema; Rieneke van de Ven; Gerben J. C. Zwezerijnen; Pim de Graaf; K. Hakki Karagozoglu; Jan Hendrickx; Simone E. J. Eerenstein; Rolf J. Bun; Dorien C Mulder; Jens Voortman; Ronald Boellaard; Albert D. Windhorst; J Pascal Hagers; Laura A. N. Peferoen; Tanja D. de Gruijl; Elisabeth Bloemena; Ruud H. Brakenhoff; C. René Leemans; C. Willemien Menke‐van der Houven van Oordt

doi:10.1136/jitc-2024-009278

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Addition of neoadjuvant immune checkpoint inhibition to standard-of-care interventions for locally advanced oral cancer could improve clinical outcome.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wondergem et al. (2024) studied this question.

synapsesocial.com/papers/68e61e05b6db6435875b0774 https://doi.org/10.1136/jitc-2024-009278

View Full Paper

Ask AI

Bookmark

Share

Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading